(firstQuint)A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers.

 This is an open-label, single arm, dose escalation study in patients with advanced cancers.

 Treatment will be administered on an outpatient basis.

.

 A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers@highlight

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

